Literature DB >> 15009794

Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Vickie L Shavers1, Martin L Brown, Arnold L Potosky, Carrie N Klabunde, W W Davis, Judd W Moul, Angela Fahey.   

Abstract

INTRODUCTION: Several recent studies have noted that African Americans disproportionately receive "watchful waiting" for the initial management of their prostate cancer. To determine whether racial/ethnic differences in the receipt of watchful waiting are explained by differences in clinical presentation and life expectancy at the time of diagnosis, we examined Surveillance, Epidemiology, and End Results (SEER)-Medicare data for men diagnosed with prostate cancer in 1994 to 1996.
METHODS: Race/ethnicity, comorbidity, stage, grade, age, and expected lifespan and their association with the receipt of watchful waiting were examined in multivariate logistic regression analyses. Race-stratified logistic regression analyses were also used to examine racial/ethnic variation in the association of clinical and demographic factors with the receipt of watchful waiting among African-American, Hispanic, and non-Hispanic white men.
RESULTS: African-American (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.3 to 1.6) and Hispanic men (OR, 1.3; 95% CI, 1.1 to 1.5) were significantly more likely than non-Hispanic white men to receive watchful waiting in a multivariate model adjusted for age, comorbidity, stage, grade, and life expectancy. Advanced stage and grade, lower life expectancy, older age, and high comorbidity indices were also significantly associated with an increase in the odds of receipt of watchful waiting in multivariate analyses. In general, the association between the receipt of watchful waiting and the clinical characteristics (i.e., stage, grade, and age) were similar for the three racial/ethnic groups. In race-stratified logistic regression analyses, life expectancy was associated with an increase in the odds of receiving watchful waiting but results were statistically significant for whites only. There was also a statistically significant increase in the odds of receiving watchful waiting for African-American and white men with high comorbidity indices but not Hispanic men. The odds of receiving watchful waiting were also higher for African-American and Hispanic men who resided in census tracts where a large percentage of residents had not completed high school than for white men who resided in similar census tracts.
CONCLUSION: The disproportionate receipt of watchful waiting among African Americans and Hispanics is not completely explained by racial/ethnic variation in clinical characteristics or life expectancy as measured in this study. These data suggest that there are other factors that contribute to racial/ethnic differences in receipt of watchful waiting that warrant investigation.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health

Mesh:

Year:  2004        PMID: 15009794      PMCID: PMC1492143          DOI: 10.1111/j.1525-1497.2004.30209.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  41 in total

Review 1.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

2.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

3.  Radiation therapy in non-surgically-treated nonmetastatic prostate cancer: geographic and demographic variation.

Authors:  S Lai; H Lai; S Lamm; C Obek; A Krongrad; B Roos
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

4.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

5.  Ethnic variation in prostate cancer survival in New Mexico.

Authors:  F D Gilliland; W C Hunt; C R Key
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-04       Impact factor: 4.254

6.  PSA screening and prostate cancer mortality.

Authors:  Linda Perron; Lynne Moore; Isabelle Bairati; Paul-Marie Bernard; François Meyer
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

7.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.

Authors:  S J Jacobsen; S K Katusic; E J Bergstralh; J E Oesterling; D Ohrt; G G Klee; C G Chute; M M Lieber
Journal:  JAMA       Date:  1995-11-08       Impact factor: 56.272

8.  Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.

Authors:  Robert A Stephenson
Journal:  Urol Clin North Am       Date:  2002-02       Impact factor: 2.241

9.  A preliminary report on a patient-preference study to compare treatment options in early prostate cancer.

Authors: 
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

10.  Use of SEER-Medicare data for measuring cancer surgery.

Authors:  Gregory S Cooper; Beth Virnig; Carrie N Klabunde; Nicola Schussler; Jean Freeman; Joan L Warren
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

View more
  59 in total

1.  Racial differences in well-being and cancer concerns in prostate cancer patients.

Authors:  Sumedha Chhatre; Alan J Wein; S Bruce Malkowicz; Ravishankar Jayadevappa
Journal:  J Cancer Surviv       Date:  2011-01-28       Impact factor: 4.442

2.  The challenges of understanding and eliminating racial and ethnic disparities in health.

Authors:  JudyAnn Bigby; Eliseo Pérez-Stable
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

3.  Men's perspectives on selecting their prostate cancer treatment.

Authors:  Jinping Xu; Rhonda K Dailey; Susan Eggly; Anne Victoria Neale; Kendra L Schwartz
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

Review 4.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

5.  Geriatric assessment-identified deficits in older cancer patients with normal performance status.

Authors:  Trevor A Jolly; Allison M Deal; Kirsten A Nyrop; Grant R Williams; Mackenzi Pergolotti; William A Wood; Shani M Alston; Brittaney-Belle E Gordon; Samara A Dixon; Susan G Moore; W Chris Taylor; Michael Messino; Hyman B Muss
Journal:  Oncologist       Date:  2015-03-12

6.  Variation in quality of care among older men with localized prostate cancer.

Authors:  Ravishankar Jayadevappa; Sumedha Chhatre; Jerry C Johnson; S Bruce Malkowicz
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

7.  Is prostate cancer different in black men? Answers from 3 natural history models.

Authors:  Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni
Journal:  Cancer       Date:  2017-04-24       Impact factor: 6.860

8.  The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy.

Authors:  Kyna M Gooden; Daniel L Howard; William R Carpenter; April P Carson; Yhenneko J Taylor; Sharon Peacock; Paul A Godley
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

9.  Race, healthcare access and physician trust among prostate cancer patients.

Authors:  Young Kyung Do; William R Carpenter; Pamela Spain; Jack A Clark; Robert J Hamilton; Joseph A Galanko; Anne Jackman; James A Talcott; Paul A Godley
Journal:  Cancer Causes Control       Date:  2009-09-24       Impact factor: 2.506

10.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Authors:  Kendra Schwartz; Isaac J Powell; Willie Underwood; Julie George; Cecilia Yee; Mousumi Banerjee
Journal:  Urology       Date:  2009-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.